| General Information | |
|---|---|
| ZINC ID | ZINC000095585007 |
| Molecular Weight (Da) | 443 |
| SMILES | CCN(CC)c1ccc(CN(c2ccc(Cl)cc2)S(=O)(=O)c2cccc(C)c2)cc1 |
| Molecular Formula | C24Cl1N2O2S1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 126.17 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 30 |
| LogP | 6.117 |
| Activity (Ki) in nM | 2.818 |
| Polar Surface Area (PSA) | 49 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | + |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.92546898 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.25 |
| Ilogp | 3.84 |
| Xlogp3 | 5.97 |
| Wlogp | 6.82 |
| Mlogp | 4.71 |
| Silicos-it log p | 4.53 |
| Consensus log p | 5.17 |
| Esol log s | -6.26 |
| Esol solubility (mg/ml) | 0.000241 |
| Esol solubility (mol/l) | 0.00000054 |
| Esol class | Poorly sol |
| Ali log s | -6.78 |
| Ali solubility (mg/ml) | 0.0000743 |
| Ali solubility (mol/l) | 0.00000016 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.9 |
| Silicos-it solubility (mg/ml) | 0.00000055 |
| Silicos-it solubility (mol/l) | 1.25E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.76 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 2 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.26 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.609 |
| Logd | 4.551 |
| Logp | 6.32 |
| F (20%) | 0.006 |
| F (30%) | 0.007 |
| Mdck | 9.10E-06 |
| Ppb | 0.999 |
| Vdss | 0.587 |
| Fu | 0.007 |
| Cyp1a2-inh | 0.478 |
| Cyp1a2-sub | 0.831 |
| Cyp2c19-inh | 0.925 |
| Cyp2c19-sub | 0.24 |
| Cl | 5.832 |
| T12 | 0.061 |
| H-ht | 0.194 |
| Dili | 0.987 |
| Roa | 0.315 |
| Fdamdd | 0.285 |
| Skinsen | 0.065 |
| Ec | 0.003 |
| Ei | 0.056 |
| Respiratory | 0.472 |
| Bcf | 2.105 |
| Igc50 | 4.981 |
| Lc50 | 5.727 |
| Lc50dm | 6.725 |
| Nr-ar | 0.013 |
| Nr-ar-lbd | 0.008 |
| Nr-ahr | 0.42 |
| Nr-aromatase | 0.954 |
| Nr-er | 0.715 |
| Nr-er-lbd | 0.031 |
| Nr-ppar-gamma | 0.072 |
| Sr-are | 0.857 |
| Sr-atad5 | 0.006 |
| Sr-hse | 0.012 |
| Sr-mmp | 0.922 |
| Sr-p53 | 0.114 |
| Vol | 447.557 |
| Dense | 0.988 |
| Flex | 0.4 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 4 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 1 |
| Qed | 0.436 |
| Synth | 2.139 |
| Fsp3 | 0.25 |
| Mce-18 | 20 |
| Natural product-likeness | -1.841 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |